Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
2.2. Search Strategy and Study Screening
2.3. Methodological Quality Assessment
2.4. Data Extraction
2.5. Statistical Analysis
3. Results
3.1. Diagnosis
3.2. Indication of Arthroscopy
3.3. Surgical Technique
3.4. Postoperative Rehabilitation
3.5. Final Reported Outcomes
3.6. Complications
4. Discussion
5. Limitations and Future Directions
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Zenginkinet, T.; Faruq, A.U.; Toksoz Yildirim, A.N.; Iyetin, Y.; Ozturan, B.; Okay, E.; Celik, A.; Ozkan, K.; Akyurek, M. PD-L1 Status in Tenosynovial Giant Cell Tumors. Medicina 2022, 58, 1270. [Google Scholar] [CrossRef] [PubMed]
- Chang, K.J.; Byun, B.H.; Moon, H.S.; Park, J.; Koh, J.S.; Kim, B.I.; Lim, S.M. Tenosynovial Giant Cell Tumor of Diffuse Type Mimicking Bony Metastasis Detected on F-18 FDG PET/CT. Nucl. Med. Mol. Imaging 2014, 48, 230–232. [Google Scholar] [CrossRef] [PubMed]
- Nishio, J.; Nakayama, S.; Koga, K.; Aoki, M. Giant Cell Tumor of Soft Tissue: An Updated Review. J. Clin. Med. 2024, 13, 2870. [Google Scholar] [CrossRef] [PubMed]
- West, R.B.; Rubin, B.P.; Miller, M.A.; Subramanian, S.; Kaygusuz, G.; Montgomery, K.; Zhu, S.; Marinelli, R.J.; De Luca, A.; Downs-Kelly, E.; et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc. Natl. Acad. Sci. USA 2006, 103, 690–695. [Google Scholar] [CrossRef]
- Somerhausen, N.d.S.A.; van de Rijn, M. Tenosynovial Giant Cell Tumour. In 5th World Health Organization Classification of Tumours of Soft Tissue and Bone, 5th ed.; WHO Classification of Tumours Editorial, Ed.; IARC Press: Lyon, France, 2020; pp. 133–136. [Google Scholar]
- Kager, M.; Kager, R.; Fałek, P.; Fałek, A.; Szczypiór, G.; Niemunis-Sawicka, J.; Rzepecka-Wejs, L.; Starosławska, E.; Burdan, F. Tenosynovial giant cell tumor. Folia Med. Cracov. 2022, 62, 93–107. [Google Scholar]
- Ehrenstein, V.; Andersen, S.L.; Qazi, I.; Sankar, N.; Pedersen, A.B.; Sikorski, R.; Acquavella, J.F. Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark. J. Rheumatol. 2017, 44, 1476–1483. [Google Scholar] [CrossRef]
- Myers, B.W.; Masi, A.T. Pigmented villonodular synovitis and tenosynovitis: A clinical epidemiologic study of 166 cases and literature review. Medicine 1980, 59, 223–238. [Google Scholar] [CrossRef]
- Xie, G.P.; Jiang, N.; Liang, C.X.; Zeng, J.C.; Chen, Z.Y.; Xu, Q.; Qi, R.Z.; Chen, Y.R.; Yu, B. Pigmented villonodular synovitis: A retrospective multicenter study of 237 cases. PLoS ONE 2015, 10, e0121451. [Google Scholar] [CrossRef]
- Gouin, F.; Noailles, T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop. Traumatol. Surg. Res. 2017, 103, S91–S97. [Google Scholar] [CrossRef]
- Ottaviani, S.; Ayral, X.; Dougados, M.; Gossec, L. Pigmented villonodular synovitis: A retrospective single-center study of 122 cases and review of the literature. Semin. Arthritis Rheum. 2011, 40, 539–546. [Google Scholar] [CrossRef]
- Mankin, H.; Trahan, C.; Hornicek, F. Pigmented villonodular synovitis of joints. J. Surg. Oncol. 2011, 103, 386–389. [Google Scholar] [CrossRef] [PubMed]
- González Della Valle, A.; Piccaluga, F.; Potter, H.G.; Salvati, E.A.; Pusso, R. Pigmented villonodular synovitis of the hip: 2- to 23-year followup study. Clin. Orthop. Relat. Res. 2001, 388, 187–199. [Google Scholar] [CrossRef] [PubMed]
- Hufeland, M.; Gesslein, M.; Perka, C.; Schröder, J.H. Long-term outcome of pigmented villonodular synovitis of the hip after joint preserving therapy. Arch. Orthop. Trauma Surg. 2018, 138, 471–477. [Google Scholar] [CrossRef] [PubMed]
- Mollon, B.; Lee, A.; Busse, J.W.; Griffin, A.M.; Ferguson, P.C.; Wunder, J.S.; Theodoropoulos, J. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: An individual patient meta-analysis. Bone Jt. J. 2015, 97, 550–557. [Google Scholar] [CrossRef]
- Zook, J.E.; Wurtz, D.L.; Cummings, J.E.; Cárdenes, H.R. Intra-articular chromic phosphate (32P) in the treatment of diffuse pigmented villonodular synovitis. Brachytherapy 2011, 10, 190–194. [Google Scholar] [CrossRef]
- Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J. Clin. Epidemiol. 2009, 62, e1–e34. [Google Scholar] [CrossRef]
- Burns, P.B.; Rohrich, R.J.; Chung, K.C. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 2011, 128, 305–310. [Google Scholar] [CrossRef]
- Ramponi, L.; Yasui, Y.; Murawski, C.D.; Ferkel, R.D.; Di Giovanni, C.W.; Kerkhoffs, G.M.M.J.; Calder, J.D.F.; Takao, M.; Vannini, F.; Choi, W.J.; et al. Lesion Size Is a Predictor of Clinical Outcomes After Bone Marrow Stimulation for Osteochondral Lesions of the Talus: A Systematic Review. Am. J. Sports Med. 2017, 45, 1698–1705. [Google Scholar] [CrossRef]
- Giai Via, R.; Migliorini, F.; Bosco, F.; Onorato, F.; Secco, D.C.; Giustra, F.; Lavia, A.D.; Giachino, M.; Massè, A. Superior outcomes of total hip arthroplasty without prior lumbar arthrodesis: A systematic review and meta-analysis. Eur. J. Orthop. Surg. Traumatol. 2024, 34, 699–711. [Google Scholar] [CrossRef]
- Sideri, S.; Papageorgiou, S.N.; Eliades, T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J. Clin. Epidemiol. 2018, 100, 103–110. [Google Scholar] [CrossRef]
- Li, T.; Mei, L.; Xu, Y.; Cao, Y.; Shi, X.; Chen, G.; Li, J. Total Hip Arthroplasty or Arthroscopy for Pigmented Villonodular Synovitis of the Hip: A Retrospective Study with 3-Year Follow-Up at Minimum. Orthop. Surg. 2023, 15, 1498–1504. [Google Scholar] [CrossRef] [PubMed]
- Sun, H.; Ju, X.D.; Huang, H.J.; Zhang, X.; Wang, J.Q. Clinical outcomes of endoscopic synovectomy with adjuvant radiotherapy of pigmented villonodular synovitis of the hip: A case series of single center. BMC Musculoskelet. Disord. 2022, 23, 192. [Google Scholar] [CrossRef] [PubMed]
- Willimon, S.C.; Schrader, T.; Perkins, C.A. Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip in Children and Adolescents. Orthop. J. Sports Med. 2018, 6, 2325967118763118. [Google Scholar] [CrossRef] [PubMed]
- Nazal, M.R.; Parsa, A.; Gibbs, J.S.; Abraham, P.F.; Martin, S.D. Mid-Term Results of Arthroscopic Synovectomy for Pigmented Villonodular Synovitis of the Hip. Arthroscopy 2020, 36, 1587–1598. [Google Scholar] [CrossRef]
- Tang, H.C.; Sadakah, M.; Wirries, N.; Dienst, M. Outcomes of arthroscopic management for pigmented villonodular synovitis of the hip. Arch. Orthop. Trauma Surg. 2022, 142, 2811–2818. [Google Scholar] [CrossRef]
- Byrd, J.W.; Jones, K.S.; Maiers, G.P., 2nd. Two to 10 Years’ follow-up of arthroscopic management of pigmented villonodular synovitis in the hip: A case series. Arthroscopy 2013, 29, 1783–1787. [Google Scholar] [CrossRef]
- Stephan, S.R.; Shallop, B.; Lackman, R.; Kim, T.W.B.; Mulcahey, M.K. Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm. JBJS Rev. 2016, 4, e3. [Google Scholar] [CrossRef]
- Rodriguez-Merchan, E.C. Review article: Open versus arthroscopic synovectomy for pigmented villonodular synovitis of the knee. J. Orthop. Surg. 2014, 22, 406–408. [Google Scholar] [CrossRef]
- Botez, P.; Sirbu, P.D.; Grierosu, C.; Mihailescu, D.; Savin, L.; Scarlat, M.M. Adult multifocal pigmented villonodular synovitis—Clinical review. Int. Orthop. 2013, 37, 729–733. [Google Scholar] [CrossRef]
- Friedman, T.; Chen, T.; Chang, A. MRI diagnosis of recurrent pigmented villonodular synovitis following total joint arthroplasty. HSS J. 2013, 9, 100–105. [Google Scholar] [CrossRef]
- Lee, S.; Haro, M.S.; Riff, A.; Bush-Joseph, C.A.; Nho, S.J. Arthroscopic technique for the treatment of pigmented villonodular synovitis of the hip. Arthrosc. Tech. 2015, 4, e41–e46. [Google Scholar] [CrossRef] [PubMed]
- McCormick, F.; Alpaugh, K.; Haughom, B.; Nho, S. Arthroscopic T-capsulotomy for excision of pigmented villonodular synovitis in the hip. Orthopedics 2015, 38, 237–239. [Google Scholar] [CrossRef] [PubMed]
- Massè, A.; Aprato, A.; Alluto, C.; Favuto, M.; Ganz, R. Surgical hip dislocation is a reliable approach for treatment of femoral head fractures. Clin. Orthop. Relat. Res. 2015, 473, 3744–3751. [Google Scholar] [CrossRef] [PubMed]
- Ganz, R.; Gill, T.J.; Gautier, E.; Ganz, K.; Krügel, N.; Berlemann, U. Surgical dislocation of the adult hip a technique with full access to the femoral head and acetabulum without the risk of avascular necrosis. J. Bone Jt. Surg. Br. 2001, 83, 1119–1124. [Google Scholar] [CrossRef]
- Mimura, T.; Kawasaki, T.; Yagi, K.; Mori, K.; Imai, S.; Matsusue, Y. Pigmented villonodular synovitis causing osteonecrosis of the femoral head: A case report. Case Rep. Orthop. 2013, 2013, 756954. [Google Scholar] [CrossRef]
- Levy, D.M.; Haughom, B.D.; Nho, S.J.; Gitelis, S. Pigmented Villonodular Synovitis of the Hip: A Systematic Review. Am. J. Orthop. 2016, 45, 23–28. [Google Scholar]
- Cheok, T.; Wills, K.; Berman, M.; Jennings, M.P.; Poonnoose, P.M. Open or Arthroscopic Synovectomy Is the Preferred Management Option in Pigmented Villonodular Synovitis of the Hip Joint Without Evidence of Degeneration: A Systematic Review of 20 Studies. Arthrosc. Sports Med. Rehabil. 2022, 4, e1873–e1886. [Google Scholar] [CrossRef]
- Bernthal, N.M.; Ishmael, C.R.; Burke, Z.D.C. Management of Pigmented Villonodular Synovitis (PVNS): An Orthopedic Surgeon’s Perspective. Curr. Oncol. Rep. 2020, 22, 63. [Google Scholar] [CrossRef]
- Cassier, P.A.; Gelderblom, H.; Stacchiotti, S.; Thomas, D.; Maki, R.G.; Kroep, J.R.; van der Graaf, W.T.; Italiano, A.; Seddon, B.; Dômont, J.; et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 2012, 118, 1649–1655. [Google Scholar] [CrossRef]
- Fiocco, U.; Sfriso, P.; Oliviero, F.; Sovran, F.; Scagliori, E.; Pagnin, E.; Vezzu, M.; Cozzi, L.; Botsios, C.; Nardacchione, R.; et al. Trattamento intra-articolare con l’antagonista del TNFalpha etanercept nella sinovite villo-nodulare pigmentosa diffusa del ginocchio [Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee]. Reumatismo 2006, 58, 268–274. [Google Scholar]
Authors (year) | Study Design (LoE) | No. of Patients (N) | Age (years), Mean ± SD (Range) | Male/Female (N/N) | Left/Right (N/N) | Type (Diffuse/Nodular/Combined) (N/N) | BMI (kg/m2), Mean ± SD (Range) | FU (mns) Mean ± SD (Range) | Symptomatic Period (mns), Mean ± SD (Range) |
---|---|---|---|---|---|---|---|---|---|
Li et al. (2023) [22] | Retrospective (IV) | 20 | 34.2 ± 10.2 | 10/10 | 8/12 | / | 21.7 ± 2.1 (18.67–25.95) | 50.3 ± 22.46 | / |
Sun et al. (2022) [23] | Retrospective (IV) | 16 | 29.5 (16–66) | 8/8 | / | 12/4/0 | 21.8 (16.2–27.3) | 44.8 ± 38.2 (3–110) | 16.9 (1–60) |
Willimon et al. (2018) [24] | Retrospective (IV) | 5 | 11 (4–17) | 2/3 | 3/2 | 1/4/0 | / | 32 (12–63) | 8.2 (0.1–31.1) |
Nazal et al. (2020) [25] | Retrospective (IV) | 14 | 32.69 ±12.7 (16–55) | 6/8 | 6/8 | 5/9/0 | 27.8 ± 3.46 (21.8–31.7) | 79.9 ± 22.4 | 21.33 ± 29.2 (2–108) |
Tang et al. (2022) [26] | Retrospective (IV) | 9 | 24.3 ± 11.2 (14–44) | 2/7 | / | 5/4/0 | / | 55.8 ± 26.1 (24–84) | 25.2 ± 24.4 (0.5- 60) |
Byrd et al. (2013) [27] | Prospective (IV) | 13 | 26.8 (14–46) | 9/4 | / | 3/3/7 | / | 63 (24–120) | 17 (2–60) |
Authors (year) | Misdiagnosis (N) | MRI Diagnosis N (%) | Tönnis Grading (N, %) | Concomitant Pathology (N, %) |
---|---|---|---|---|
Li et al. (2023) [22] | / | / | / | Femoral head AVN (2, 10%), OA (3, 15%) |
Sun et al. (2022) [23] | Inflammation (1), rheumatoid arthritis (1), femoral head AVN (1), synovial chondromatosis (2). | / | Head cartilage injury: Degree IV (5), degree III (4), degree II (4), and degree I (3). Acetabular cartilage injury: degree IV (5), degree III (1), degree II (1). | Labral tears (3, 18.8%), FAI (4, 25%). |
Willimon et al. (2018) [24] | Transient synovitis (2), FAI (1), femoral neck stress fracture (1), bleeding disorder (1). | 4 (80%) | / | / |
Nazal et al. (2020) [25] | / | 7 (50%) | Grade 1: (8, 57.1%), grade 2: (4, 28.6%), grade 3: (1, 7.1%). | Labral tears (5, 35.7%), FAI (10, 71.4%). |
Tang et al. (2022) [26] | Groin or hip pain (7), coxa valga (1), hip effusion (1). | 4 (44.4%) | / | Decreased internal rotation (< 15°) (6, 66.7%), FAI (6, 66.7%). |
Byrd et al. (2013) [27] | / | 6 (46%) | / | Cartilage lesions (7, 53.8%), labral tears (6, 46%), FAI (4, 30.8%). |
Authors (year) | Position | Operation Time (min), Mean ± SD (Range) | Surgical Technique (N) | Adjuvant Therapy (N) | Postoperative Protocol |
---|---|---|---|---|---|
Li et al. (2023) [22] | Supine | 103.1 ± 39 | Focal or diffuse arthroscopic synovectomy (detailed) | (0) | / |
Sun et al. (2022) [23] | / | / | Arthroscopic synovectomy (name only) + labral repair (3) + Femoral osteoplasty (4) + Acetabuloplasty (2) + labral debridement (2) | PO radiotherapy (8) | / |
Diffuse (6)–Localized (2) | |||||
Willimon et al. (2018) [24] | / | / | Arthroscopic synovectomy (name only) | / | / |
Nazal et al. (2020) [25] | Supine | 96 ± 29.95 (60–144) | Focal or diffuse arthroscopic synovectomy + concomitant pathology (detailed) | / | WB with crutches for 6 weeks |
After 6 weeks, one then no crutches + start rehabilitation | |||||
Tang et al. (2022) [26] | Supine | / | Subtotal synovectomy (detailed) | Radiosynoviorthesis (5) | Partial WB for the first 2 weeks and then full WB allowed |
Continuous passive and active ROM exercises recommended for first 4–6 weeks to prevent adhesions | |||||
Byrd et al. (2013) [27] | Supine | / | Excision diseased synovium + concomitant pathology (not detailed) | / | / |
Authors (year) | Pre-Op Outcome Measures, Mean ± SD (Range) | Post-Op Outcome Measures, Mean ± SD (Range) | Success Rate (N/N, %) | Recurrence (N, %) | Revision (N) | Complication (N) | THA Conversion |
---|---|---|---|---|---|---|---|
Li et al. (2023) [22] | VAS 4.05 ± 0.94 HHS 45.30 ± 11.08 (25–64) | VAS 1.35 ± 1.79 HHS 71.6± 19.78 (46–95) | 16/20 (80%) | 4 (20%) | 0 | 0 | 4 |
Sun et al. (2022) [23] | HOS ADL 63.1 ± 19.1(32–98.3) mHHS 54.8 ± 20.1 (10–77) iHOT-12 50.9 ± 15.4 (31–76.6) NAHS 51.6 ± 15.9 (20–84.4) VAS 6 ± 1.4 (4–8) | HOS ADL 79.7 ± 10.8 (58–97.6) mHHS 78.6 ± 9.1 (55.0–87) iHOT-12 74.7 ± 9.7 (55.6–91) NAHS 78.9 ± 18.7 (20.0–92.5) VAS 3.1 ± 1.2 (2–6) | 13/16 (81%) | 0 | 0 | OA, 3 | 3 |
Willimon et al. (2018) [24] | / | Return to activities (4) MRI free of PVNS (3) | 4/5 (80%) | 0 | 0 | OA, 1 | 0 |
Nazal et al. (2020) [25] | VAS 8.1 ± 1.1 | VAS 3.2 ± 1.8 mHHS 74.1± 16 NAHS 78.9 ± 20 LEFS 64.9 ±17.9 HOS ADL 57.5 ± 12.5 HOS-SSS 73.7 ± 29.2 iHOT-33 67.9 ± 27.4 | 14/14 100% | 1/14 (7.14%) | 1, Arthroscopic | 0 | 0 |
Tang et al. (2022) [26] | / | mHHS 94.6 ± 4.9 (84.7–100) iHOT-12 93.3 ± 20.2 (50–120) | 9/9 100% | 0 | 0 | 0 | 0 |
Byrd et al. (2013) [27] | mHHS 62 ± 17 | mHHS 89 ± 17 mHHS improvement 27 (3–56) | 12/13 (92%) | 1/13 (7.69%) | 0 | Residual synovitis, 1; mild effusion, 3 | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Giai Via, R.; Giachino, M.; Elzeiny, A.; Santarsiero, G.; Cipolla, A.; Pantè, S.; Bosco, F.; Zoccola, K.; Massè, A.; Aprato, A. Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip: A Systematic Review. J. Clin. Med. 2024, 13, 6446. https://doi.org/10.3390/jcm13216446
Giai Via R, Giachino M, Elzeiny A, Santarsiero G, Cipolla A, Pantè S, Bosco F, Zoccola K, Massè A, Aprato A. Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip: A Systematic Review. Journal of Clinical Medicine. 2024; 13(21):6446. https://doi.org/10.3390/jcm13216446
Chicago/Turabian StyleGiai Via, Riccardo, Matteo Giachino, Ahmed Elzeiny, Gianvito Santarsiero, Alessandra Cipolla, Salvatore Pantè, Francesco Bosco, Kristijan Zoccola, Alessandro Massè, and Alessandro Aprato. 2024. "Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip: A Systematic Review" Journal of Clinical Medicine 13, no. 21: 6446. https://doi.org/10.3390/jcm13216446
APA StyleGiai Via, R., Giachino, M., Elzeiny, A., Santarsiero, G., Cipolla, A., Pantè, S., Bosco, F., Zoccola, K., Massè, A., & Aprato, A. (2024). Arthroscopic Management of Pigmented Villonodular Synovitis of the Hip: A Systematic Review. Journal of Clinical Medicine, 13(21), 6446. https://doi.org/10.3390/jcm13216446